Neumora Names New CEO, Extends Cash Runway to Q3 2027, and Sets Key Pipeline Milestones
NMRA sits 99% above its 52-week low of $0.83 on light trading volume (0.3× avg).
Summary
Neumora reported Q2 2026 results with $116.8M in cash, enough to fund operations into Q3 2027. R&D spending dropped to $29.3M from $38.7M a year earlier, reflecting the June discontinuation of its lead depression drug. The company appointed Joshua Pinto as CEO and Doron Sagman as CMO, signaling a leadership reset after the Phase 3 failure. Pipeline focus shifts to NMRA-215 (obesity), NMRA-511 (Alzheimer's agitation), and NMRA-898 (schizophrenia), with multiple data readouts expected in H2 2026. The extended runway and disciplined spending reduce near-term dilution risk, but the stock remains a clinical-stage bet on early data.
At the time of this announcement, NMRA was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.5M. The 52-week trading range was $0.83 to $3.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.